Table 2.
Ref. | Study/setting | Treatment | No. of patients | Response rate | Median PFS/TTP and OS (mo) |
Anti-HER2 agents | |||||
Bang et al[8] | ToGA/first-line | Trastuzumab + CX/CF vs CX/CF | 584 | 47% vs 35% | PFS, 6.7 vs 5.5; OS, 13.8 vs 11.1 |
Bang et al[47] | TyTAN/second-line | Lapatinib + P vs P | 430 | NA | PFS, 5.4 vs 4.4; OS, 11.0 vs 8.9 |
Hecht et al[48] | TRIO-013/LOGiC/first-line | Lapatinib + CAPOX vs CAPOX | 545 | 53% vs 40% | PFS, 6.0 vs 5.4; OS, 12.2 vs 10.5 |
Anti EGFR1 agents | |||||
Lordick et al[55] | EXPAND/first-line | Cetuximab + CX vs CX | 904 | 29% vs 30% | PFS, 4.4 vs 5.6; OS, 9.4 vs 10.7 |
Waddell et al[56] | REAL-3/first-line | Panitumumab + mEOX vs EOX | 553 | 42% vs 46% | PFS, 6.0 vs 7.4; OS, 8.8 vs 11.3 |
Anti-VEGF agents | |||||
Ohtsu et al[64] | AVAGAST/first-line | Bevacizumab + CX vs placebo + CX | 774 | 46% vs 37.4% | PFS, 6.7 vs 5.3; OS, 12.1 vs 10.1 |
mTOR inhibitors | |||||
Ohtsu et al[76] | GRANITE-1/first-line | Everolimus + BSC vs placebo + BSC | 656 | 4.5% vs 2.1% | PFS, 1.7 vs 1.4; OS, 5.4 vs 4.3 |
HER2: Human epidermal growth factor receptor 2; EGFR1: Epidermal growth factor receptor 1; VEGF: Vascular endothelial growth factor; mTOR: Mammalian target of rapamycin; CX: Cisplatin and capecitabine; CF: Cisplatin and fluorouracil; P: Paclitaxel; CAPOX: Capecitabine and oxaliplatin; EOX: Epirubicin, oxaliplatin and capecitabine; mEOX: Modified EOX; BSC: Best supportive care; PFS: Progression-free survival; TTP: Time-to progression; OS: Overall survival; NA: Not applicable.